# CLBT — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-09-15. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 5.5 · Fundamentals 6.2 · Technicals 3.8 · Growth 5.8 · Risk 6.8

## Summary

Cellebrite is a high-gross-margin (~83%) digital forensics franchise with a fortress balance sheet ($442M cash, $125M TTM FCF, net cash ~15% of market cap), but the investment case is fractured by a Q2'26 operating margin collapse from 16.2% to 5.3%, a cut FY26 guide, CEO transition, and $4.7M of insider selling. With the stock at $11.23 down ~35% YTD and Nov 11 earnings ~57 days away, the setup is a asymmetric wait — cheap on FCF/cash, but momentum broken and prior bullish targets have systematically failed to print.

## Price targets (6-month horizon)

- Bear: $9.50
- Base: $13.00
- Bull: $15.50

## News context

The dominant signal is the Q2'26 miss and guidance cut (revenue trimmed, EPS $0.02 vs $0.06 est., a 66% miss) that drove the ~30% breakdown, followed by two sell-side PT cuts in mid-August ($21.29 → $19.43 → $16.86). Layered on top: CEO transition to Shiven Ramji (product-led growth mandate), CTO Chris Wade elevated to lead Cellebrite Labs, and a Sep 14 authorization to pursue U.S. redomicile. Product/procurement wins are real but incremental — Guardian achieved IRAP PROTECTED (Australian federal), CFSI achieved CMMC Level 2 (U.S. DoD). Sell-side is engaged (Craig-Hallum, DA Davidson calls, September investor events).

Signal: margin trajectory and guide credibility dominate everything else — Nov 11 is the true catalyst. Noise: redomicile is a slow-burn optionality item (shareholder/regulatory approval required, could easily be a 'sell the news' event), and IRAP/CMMC are marginal revenue impact near-term. Insider selling by outgoing CEO ($2.1M + $286k) is contextually explainable but pattern-wise unhelpful — clusters of executive selling on this name have preceded further downside, not marked bottoms.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/clbt-ai-stock-forecast-4ef6bebc7defb524ba2aaed4d557f9a4
- AI-generated; model outputs can be wrong. Not financial advice.